glp-1 with testosterone drugs may boost male fertility, and sperm health Health Rounds: GLP-1 obesity drugs

First, epidemiological data reveal that patients with T2D and cardiovascular disease receiving GLP-1RAs have substantial reductions in the risk of developing all-cause dementia

Under these nonpathological conditions, coupling of glucose metabolism to K ATP channel closure is not disturbed, so that glucose is fully capable of generating the cytosolic Ca 2+ signal that stimulates insulin exocytosis

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial

[DOI] [PubMed] [Google Scholar] 125.Jalleh RJ, et al

47 In addition, the effect was evaluated in the absence or presence of the DDP-4 inhibitor Val-Pyr